Form 4: Avidity CTO Sells Shares, Options Amid Novartis Merger

Avidity Biosciences' Chief Technical Officer, Charles Calderaro III, disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger agreement with Novartis AG.

Summary

• Charles Calderaro III, Chief Technical Officer of Avidity Biosciences, Inc. (RNAM), reported a disposition of securities.
• The transaction occurred on February 27, 2026.
• The disposition included 98,547 shares of Common Stock.
• Additionally, 80,000 Stock Options with an exercise price of $31.42 were disposed of.
• These transactions were executed pursuant to the Agreement and Plan of Merger, dated October 25, 2025, between Novartis AG, Ajax Acquisition Sub, Inc., and Avidity Biosciences, Inc.
• The Stock Options were disposed of in exchange for a cash payment equal to the excess of the merger consideration of $72.00 per share over the option's exercise price.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development for Avidity Biosciences shareholders, as the merger consideration represents a significant premium, indicating a successful outcome for the company and its equity holders.

Positives

• The merger consideration of $72.00 per share is significantly higher than the option exercise price of $31.42, indicating a profitable transaction for the option holder.
• The disposition of securities is a result of a merger agreement, which typically provides a premium to shareholders of the acquired company.

Future Outlook

The filing reports a transaction executed as part of a merger agreement, implying the completion or near-completion of the acquisition of Avidity Biosciences by Novartis AG.

Industry Context

StockSavvy.ai notes that this transaction is a direct result of a significant M&A event in the biotechnology sector, where a large pharmaceutical company (Novartis) is acquiring a smaller biotech firm (Avidity Biosciences). This reflects a broader trend of consolidation and strategic acquisitions by major players seeking to expand their pipelines or acquire innovative technologies.

Comparison to Industry Standards

• StockSavvy.ai notes that the merger consideration of $72.00 per share, significantly above the option exercise price of $31.42, implies a substantial premium paid by Novartis for Avidity Biosciences. This aligns with industry trends in the biotechnology sector where large pharmaceutical companies acquire innovative smaller biotechs at considerable valuations, often reflecting the potential of their drug pipelines or platform technologies.
• For instance, recent acquisitions such as Pfizer's acquisition of Seagen for $43 billion (approximately $229 per share) and Merck's acquisition of Prometheus Biosciences for $10.8 billion (approximately $200 per share) also involved significant premiums over pre-announcement prices, demonstrating the high value placed on promising assets in the biopharmaceutical space. While the specific premium percentage is not detailed in this Form 4, the executive's profitable disposition of options underscores the financial benefit derived from the merger terms.

Related Party Transactions

• The disposition of securities by the Chief Technical Officer is part of a merger agreement with Novartis AG, which will become a related party upon completion of the acquisition.

Stakeholder Impact

• Shareholders: Likely positive due to the merger premium offered by Novartis AG.
• Management: The reporting person (CTO) is realizing value from their equity holdings as part of the merger, indicating a change in their equity stake and potential future role within the combined entity.

Next Steps

• Completion of the merger agreement between Avidity Biosciences and Novartis AG.

Key Dates

Recommendation

The disposition of shares and options by a key executive is a direct consequence of the announced merger agreement with Novartis AG at a consideration of $72.00 per share. For existing shareholders, holding the stock until the merger's completion allows for the realization of this value. New investors should evaluate any remaining arbitrage spread between the current market price and the $72.00 offer.

Keywords

Avidity Biosciences, RNAM, Novartis, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Common Stock, Chief Technical Officer, Charles Calderaro III